Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Breast Neoplasms

Breast Diseases

Skin Diseases

Adjuvants, Anesthesia

Anticonvulsants

Antiemetics

Central Nervous System Depressants

Muscle Relaxants, Central

Psychotropic Drugs

Gastrointestinal Agents

All Drugs and Chemicals

Diazepam

Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods

Subjects will receive bilateral (both sides) breast and axillary PEM scans.

PEM Flex Solo II PET Scanner

Subjects will receive bilateral (both sides) breast and axillary MRI scans.

MRI scan

Kirti Kulkarni, M.D.

The purpose of this study is:

1. To evaluate the hypothesis: Can PEM Flex Solo II PET scanner ascertain response to neoadjuvant chemotherapy in patients with breast cancer?
2. To compare the results from the PEM Flex Solo II PET scanner to the standard of care bilateral breast MRI.

Subjects will receive bilateral (both sides) breast and axillary PEM scans. All recruited subjects chosen for the study will have biopsy proven breast cancer and are eligible for chemotherapy. They will undergo bilateral breast MRI for staging which is considered standard of care. Breast MRI and PEM scans will be performed at at baseline (phase 0 or pre-operative phase), 2nd MRI and PEM after 1 to 2 weeks of NAC (phase 1) and 3rd MRI and PEM after 1 to 2 weeks of phase 1 (phase 2). DCE-MRI and PEM will be performed not more than 14 days apart within each phase. Cranio-Caudal (CC) and Medial Lateral Oblique (MLO) PEM views will be performed of both the ipsilateral and contralateral breast and axillae by a Mammography Technologist trained in mammographic positioning.

Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Role of PEM Flex Solo II PET Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer

Comparison of tumor size pre chemotherapy and post chemotherapy represents the PEM data. There is no the response with MRI because the study was aborted and very few patients were involved.

University of Chicago

Subject will have assessment of neoadjuvant chemotherapy treatment response by both MRI and PEM to compare methods

PEM Flex Solo II PET Scanner: Subjects will receive bilateral (both sides) breast and axillary PEM scans.

MRI scan: Subjects will receive bilateral (both sides) breast and axillary MRI scans.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer	NCT01012440	Breast Cancer	PEM Flex Solo I... MRI scan	18 Years - 75 Years	University of Chicago
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer	NCT01012440	Breast Cancer	PEM Flex Solo I... MRI scan	18 Years - 75 Years	University of Chicago
Role of Positron Emission Mammography (PEM) Flex Solo II Positron Emission Tomography (PET) Scanner in Evaluating Neoadjuvant Chemotherapy Response in Patients With Breast Cancer	NCT01012440	Breast Cancer	PEM Flex Solo I... MRI scan	18 Years - 75 Years	University of Chicago

Spots Global Cancer Trial Database for pem flex solo ii pet scanner